Unicycive Therapeutics develops novel treatments for kidney diseases, focusing on the most urgent unmet patient needs. The company’s agile development approach leverages the experience of an industry-leading team to spot overlooked technologies and transform them into commercial therapies with speed and efficiency. Unicycive’s lead investigational treatment is Oxylanthanum Carbonate (OLC), a next-generation lanthanum-based phosphate binder that uses proprietary nanoparticle technology for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis. Unicycive’s second investigational treatment, UNI-494, is intended for the treatment of conditions related to acute kidney injury. Learn more at Unicycive.com.